DVAX Stock Risk & Deep Value Analysis

Dynavax Technologies Corporation

Healthcare • Drug Manufacturers - Specialty & Generic

DVR Score

6.8

out of 10

Solid Pick

The Bottom Line on DVAX

We analyzed Dynavax Technologies Corporation using our deep value framework. Sign in to see our full verdict and DVR Score.

We ran DVAX through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Here's what we found.

Updated Dec 24, 2025•Run Fresh Analysis →

📈DVAX Performance Overview3yr weekly

📊

Unlock DVAX Performance Chart

See 3 years of price history, quarterly revenue trends, and DVR score changes

Weekly adjusted close · Quarterly revenue & EPS · DVR score history

DVAX Stock Risk Analysis

Overall Risk

Moderate

Financial Risk

Low

Market Risk

Medium

About Dynavax Technologies Corporation (DVAX)

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

Market Cap Category

small

Market Cap

$1.81B

DVAX Deep Value Analysis

Dynavax Technologies (DVAX) has significantly transformed since a hypothetical '0/100' assessment. HEPLISAV-B, their flagship Hepatitis B vaccine, has gained substantial market share, becoming a robust commercial success and driving revenue growth. The proprietary CpG 1018 adjuvant technology represents a high-potential asset, attracting partnerships (e.g., Novavax, Valneva) and generating royalty streams, positioning DVAX as a key player in next-generation vaccine development. Financial health has improved, with a path to sustained profitability. While the 10x growth target is ambitious for a commercial-stage company, the adjuvant platform's leverage and potential for multiple blockbuster vaccine contributions provide a realistic pathway, justifying a strong upward revision. Key risks include reliance on HEPLISAV-B's continued market penetration and the successful advancement of partner programs using CpG 1018.

DVAX Red Flags & Warning Signs

Premium

⚠
Failure of partner vaccines using CpG 1018 in clinical trials
⚠
Increased competitive pressure or pricing erosion for HEPLISAV-B
⚠
Regulatory setbacks for HEPLISAV-B label expansion or partner products
⚠
Unexpected manufacturing issues or supply chain disruptions

Unlock DVAX Red Flags & Risk Warnings

Premium members see every risk event we found.

📈

Unlock the full report

Create a free account to see the DVR score, risk flags, and AI analysis.

🔥 New Member Exclusive

Unlock everything for $47/yr

$79/yrSave 41%

✓ Catalysts, bull case, moat & red flags
✓ Unlimited stock analyses + alerts
✓ Full database, search & portfolio (50 stocks)

Get Premium — $47/yr

7-day money back · Cancel anytime

DVAX Financial Health Metrics

Market Cap

$1.81B

DVAX Competitive Moat Analysis

Premium

Moat Rating

Narrow

Moat Trend

Expanding

Moat Sources

2 Identified

Intangible Assets/IP (patents for CpG 1018 and HEPLISAV-B)Cost Advantages (potential for efficient scale in adjuvant manufacturing for multiple partners)

The moat is primarily driven by the proprietary CpG 1018 adjuvant, which is difficult to replicate and has been validated through multiple partnerships. The 2-dose advantage of HEPLISAV-B also provides a durable, though not insurmountable, competitive edge. Its durability hinges on continued patent protection and the successful advancement of partner programs.

DVAX Competitive Moat Analysis

Premium unlocks moat rating, sources & durability.

DVAX Catalysts & Growth Drivers

Near-Term (0-6 months)

•Q4 2025 Earnings Report (Estimated late February 2026)
•Updates on HEPLISAV-B market share expansion
•Clinical trial readouts from CpG 1018 partner programs

Medium-Term (6-18 months)

•Potential new CpG 1018 adjuvant partnership announcements
•Expansion of HEPLISAV-B into new international markets
•Progress of Valneva's Chikungunya vaccine (using CpG 1018) towards regulatory approval

Long-Term (18+ months)

•CpG 1018 becoming the adjuvant of choice for a broad range of next-generation vaccines
•Sustained global growth and leadership of HEPLISAV-B in the adult Hepatitis B vaccine market
•Internal pipeline development leveraging CpG 1018

Catalysts & Growth Drivers

Upgrade to Premium to see catalysts

DVAX Bull Case: What Could Go Right

✓
Acceleration in HEPLISAV-B sales growth beyond current expectations
✓
Announcement of new, high-value adjuvant collaborations or expanded use cases for CpG 1018
✓
Positive clinical trial data or regulatory approvals for partner vaccines utilizing CpG 1018

Bull Case Analysis

See what could go right with Premium

🔔

Never miss a move on DVAX

Create a free account to set price alerts and get notified on Telegram when DVAX hits your targets.

📊 Explore More Stock Analysis

Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential.

Analyze Any Stock →View Top 100 Deep Value Stocks →

FAQ

What is the DVR Score for Dynavax Technologies Corporation (DVAX)?

As of December 24, 2025, Dynavax Technologies Corporation has a DVR Score of 6.8 out of 10, placing it in the "Solid Pick" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.

What is the market capitalization of Dynavax Technologies Corporation?

Dynavax Technologies Corporation's market capitalization is approximately $1.8B. The company operates in the Healthcare sector within the Drug Manufacturers - Specialty & Generic industry.

What ticker symbol does Dynavax Technologies Corporation use?

DVAX is the ticker symbol for Dynavax Technologies Corporation. The company trades on the NMS.

What is the risk level for DVAX stock?

Our analysis rates Dynavax Technologies Corporation's overall risk as Moderate. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.

How often is the DVAX DVR analysis updated?

Our AI-powered analysis of Dynavax Technologies Corporation is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on December 24, 2025.

Important Disclaimer – Not Financial Advice

Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.

All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research and consult with a qualified financial advisor.